BIOVENTUS INC. (BVS) Spending and interest coverage
- R&D / revenue · 12 months: Value 1.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-27..
- Stock-based compensation / revenue · 12 months: Value 2.56%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-27..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.99% | Research and development expense / revenue. Period ending 2026-06-27. $11.57M ÷ $581.85M × 100 ≈ 1.99% |
| Stock-based compensation / revenue · 12 months | 2.56% | Share-based compensation / revenue. Period ending 2026-06-27. $14.92M ÷ $581.85M × 100 ≈ 2.56% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 11.57M USD | Research and Development Expense |
| Revenue | 581.85M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.92M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 58.28M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $11.57M | $581.85M | $14.92M | $58.28M | (m) | 1.99% | 2.56% | (m) | (m) |
| 2026-03-28 | $11.57M | $576.30M | $13.52M | $57.52M | (m) | 2.01% | 2.35% | (m) | (m) |
| 2025-12-31 | $12.11M | $568.09M | $12.67M | $53.98M | (m) | 2.13% | 2.23% | (m) | (m) |
| 2025-09-27 | $12.06M | $563.83M | $8.03M | $45.41M | (m) | 2.14% | 1.42% | (m) | (m) |
| 2025-06-28 | $12.98M | $564.14M | $7.35M | $37.80M | (m) | 2.30% | 1.30% | (m) | (m) |
| 2025-03-29 | $14.02M | $567.70M | $9.48M | $-12.04M | (m) | 2.47% | 1.67% | (m) | (m) |
| 2024-12-31 | $13.64M | $573.28M | $10.06M | $-11.98M | (m) | 2.38% | 1.75% | (m) | (m) |
| 2024-09-28 | $13.65M | $555.06M | $10.10M | $-18.80M | (m) | 2.46% | 1.82% | (m) | (m) |
| 2024-06-29 | $12.86M | $536.89M | $9.87M | $-20.46M | (m) | 2.40% | 1.84% | (m) | (m) |
| 2024-03-30 | $12.27M | $522.74M | $3.47M | $15.66M | (m) | 2.35% | 0.66% | (m) | (m) |
| 2023-12-31 | $13.45M | $512.35M | $2.72M | $-81.72M | (m) | 2.62% | 0.53% | (m) | (m) |
| 2023-09-30 | $18.22M | $502.76M | $4.38M | $-182.34M | (m) | 3.62% | 0.87% | (m) | (m) |
| 2023-07-01 | $19.82M | $510.62M | $7.19M | $-311.60M | (m) | 3.88% | 1.41% | (m) | (m) |
| 2023-04-01 | $22.78M | $513.89M | $14.54M | $-321.66M | (m) | 4.43% | 2.83% | (m) | (m) |
| 2022-12-31 | $25.94M | $512.12M | $17.59M | $-251.05M | (m) | 5.07% | 3.43% | (m) | (m) |
| 2022-10-01 | $26.24M | $516.70M | $20.26M | $-228.76M | (m) | 5.08% | 3.92% | (m) | (m) |
| 2022-07-02 | $26.55M | $496.93M | $21.55M | $-28.95M | (m) | 5.34% | 4.34% | (m) | (m) |
| 2022-04-02 | $25.02M | $466.41M | $22.79M | $-31.39M | (m) | 5.36% | 4.89% | (m) | (m) |
| 2021-12-31 | $19.04M | $430.90M | $19.84M | $12.06M | (m) | 4.42% | 4.61% | (m) | (m) |
| 2021-10-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-07-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-04-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $11.20M | $321.16M | $0.00 | $21.24M | (m) | 3.49% | 0.00% | (m) | (m) |
| 2020-09-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $11.05M | $340.14M | $0.00 | $31.19M | (m) | 3.25% | 0.00% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.